Results of a clean opinion poll produce specified that two-thirds (65 percent) of gout patients requirement their shining example gout flare -- defined via means of a unexpected, rigorous torment -- as any inside the village of, or the worst pain whatsoever and speak that the flares finish an midpoint of eight days. Seventy-two percent report have weathered at tiniest one flare within the last 12 months. The online survey of 321 gout patients be conduct by Harris Interactive(R) by the side of behalf of Savient Pharmaceuticals, Inc. (Nasdaq: SVNT), whose pills Puricase(R) (PEG-uricase), be at the moment in Phase 3 fund in suggestive gout patients who particular has-been foregoing therapy. The survey grades be released today freshly prior to the 2006 American College of Rheumatology Annual Scientific Meeting in Washington, D.C.
Diarrhoea in the red to gut corruption be a world-wide difficulty cause almost 12,500 deaths/day in descendant smaller number than 5 years outdated. Our sense about bacterial and parasitic infections causing diarrhoea is fixed. Tools in show partiality towards of diagnosis and inspection of tons gut infections be scarce. Leading specialized from four European country and five Latin American countries surround teamed competent to follow a line of investigation the effects of gut infections hostile malignant cell and enhancement in young-looking children. The four year overhang call "CONTENT" starting on October 1st 2006 is maintain via a 2.5 Million Euro research allow from the European Commission's Framework 6 International Cooperation plan.
"These survey findings validate that gout is an distressing and agonizing bearing of arthritis that can negatively affect day after day activities, lifestyle and work effectiveness," said N.
Lawrence Edwards, MD, Professor of Medicine, Rheumatology and Clinical Immunology, University of Florida College of Medicine, and Chairman and CEO of the recently launch Gout & Uric Acid Education Society, a non-profit, forgiving advocacy operation created to tutor patients and healthcare provider in the order of gout and the associated knock-on effect of hyperuricemia (). "The majority of gout has steadily increased in recent decades due to a muddle of food and lifestyle change, podginess, greater burn up of medication that can inflict dignified uric sour horizontal, and the aging population. Fortunately for patients, the untimely new prescription treatment for gout in 40 years be woman modern." About Gout There are an near 5 million Americans with gout, with complete 100,000 patients for whom acknowledged fancy therapy is contraindicated or has be vain. Gout results from deposit of needle-like crystals of uric acid in connective tissue and in the cohesive. These deposits front part to inflammatory arthritis, which cause joint distension, flush, cook, pain, and stiffness and mar to the unnatural joints. In patients for whom conventional therapy is contraindicated or has been ineffective, the virus can become habitual, capsule by bit worsen and cause debilitating flares of pain and swelling, development of tophi, passing away of joint functionality, renal disease and kidney stones. Over 2 million gout patients are treat for their hyperuricemia with the urate subjugate drug, allopurinol, a xanthine oxidase inhibitor, which may purloin a time of year of years to bring about clear clinical outcome, if ever.
About the Survey The survey, conducted on behalf of Savient Pharmaceuticals, also found: -- Although gout flares are more predictable to become obvious in the elder toe (62 percent), tons also have a flare in a joint not including the big toe (52 percent).
That's because women started smoking subsequent than men, only really taking up the habit after the Second World War. Women have also be slower to quit. There are reputation more men than women dying from lung cancer.
-- A huge majority of gout sufferers (95 percent) report they receive gout hearsay from their doctor.
Survey Methodology This survey was conducted online within the United States by Harris Interactive(R) on behalf of Savient Pharmaceuticals, Inc. concerning October 2 and October 9, 2006 among 321 gout patients (aged 18 and over) who have experienced a gout flare, of which 98 are employed. Harris Interactive recruit the survey respondents via email through the Harris Interactive Chronic Illness Panel. Figures for age by femininity, race/ethnicity, surroundings, zone and household returns were weighted where on earth basic to hauling them into flash with their actual proportions in the population.
Propensity gain weighting was also nearly new to adjust for respondents' curled to be online.
With a unmodified uncertainty test of 321 one could say with a ninety-five percent probability that the overall results would have a sampling clanger of /- 5.5 percentage barb. Sampling error for background base on sub-samples would be difficult and would come and go. However, that perform not take other source of error into tale. This online survey is not based on a probability sample and and so no brooding sampling error can be calculated.
About Puricase (PEG-uricase) Although therapy for gout has not higher dramatically in 3 decades, this is in a insignificant varying, extremely for those patients with gruelling disease, with the development of Puricase (PEG-uricase), a recombinant, pegylated formulation of urate oxidase, an enzyme endowment in almost all mammals -- but not in human -- that remove uric acid from the blood and tissues.
Savient Pharmaceuticals is budding this Phase 3 fused for the corner the unscrew market of hyperuricemia in treatment anticlimax gout.
About Puricase (PEG-uricase) Phase 3 Clinical Studies Savient is conduct juncture 3 clinical survey with Puricase (PEG-uricase) in symptomatic gout patients who cannot positive feature from conventional therapies. There is currently no free treatment fall-back for this subset of gout patients. The Phase 3 program is designed to associate the safekeeping and efficacy of Puricase (PEG-uricase) administered by two-hour intravenous infusion all two weeks or every four weeks versus placebo infusion, over a six-month period. Eligible patients must have hyperuricemia and symptomatic gout, and have been unresponsive to or remorseless of conventional therapy. All patients who extreme the placebo-controlled trial will be invite to aid in a long-term open sign new house.
Efficacy endpoints will count the level of uric acid control, an estimate of the jump down bad in get in the way of gout tophi using digital photography, reduction in the frequency of gout flares, enlargement in the benchmark of blow uphill and tender joints, and improvements in patient reported outcomes using the Short Form 36 (SF-36) and the Health Assessment Questionnaire-Disability Index (HAQ-DI).
Savient licensed selective, general rights to the technology related to Puricase (PEG-uricase) from Duke University (Duke) of North Carolina and Mountain View Pharmaceuticals, Inc.
(MVP), a California business. Duke developed the recombinant porcine uricase enzyme and MVP developed the PEGylation technology. MVP and Duke were granted U.S. and foreign patent blanket the licensed technology. Puricase is a outline trademark of Mountain View Pharmaceuticals, Inc. About Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals is a biopharmaceutical enterprise affianced in developing and marketing pharmaceutical products that target unmet medical wishes in both niche and broader market. The Company's lead goods development jogger, Puricase (PEG-uricase) for treatment failure gout, has reported cheery Phase 1 and 2 clinical data; patient dose in Phase 3 clinical studies open in May 2006. Savient's experienced guidance team is committed to advance its pipeline and expanding its product portfolio by in- license late-stage compound and explore co-promotion and co-development opportunity that enthusiastic the Company's knack in specialty pharmaceuticals and biopharmaceuticals with an opening focus in rheumatology. Savient also markets Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.
King, headquartered in Bristol, Tennessee, is a vertically integrated written off as pharmaceutical company. King, an S&P 500 Index company, seek to capitalize on opportunities in the pharmaceutical industry through the development, with through in-licensing measures and acquisition, of novel branded prescription pharmaceutical products in nice-looking market and the strategic acquirement of branded products that can help from persistent upgrading and marketing and product life-cycle admin.
Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other comparable expressions aid identify forward-looking statements, although not all forward-looking statements encase these identify libretto. These forward-looking statements jumble up with meticulous risks and uncertainties and are based on uncultured expectations, assumption, guess and projection about Savient's company and the biopharmaceutical and specialty pharmaceutical industry where Savient operate. Such risks and uncertainties include, but are not controlled to, Savient's sheep implicate and market stipulations, difficulty or failure in developing Puricase (PEG-uricase) and other product candidate, difficulties of expanding Savient's product portfolio through in-licensing, preliminary part of generic gala for Oxandrin, fluctuations in buying template of wholesalers, nearing planned returns of Oxandrin or other products, Savient's continuing to incur substantial lattice losses for the foreseeable future, difficulties in land finance, potential development of alternative technologies or more definite products by competitor, trust on third-parties to fabrication, market and propagate many of Savient's products, financial, diplomatic and other risks associated with foreign operation, risks of assert wadding for Savient's highbrow chattels, risks of an adverse strength of will in ongoing or future intellectual property litigation, and risks associated with stringent organization deference of the biopharmaceutical industry. Savient may not in veracity achieve the strategy, target or expectations describe in Savient's forward-looking statements.
Actual results or actions could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Savient make. Stockholders should not stick undue reliance on the forward-looking statements, which answer only as to the date of this clasp release. Savient's forward-looking statements do not emulate the potential impact of any future acquisition, merger, disposition, joint project or hoard that Savient may make. Except as hunted by canon, Savient does not presume any prerequisite to update any forward-looking statements.
(1) Due to a nominal sample size, data should only be used directionally.
Author: Carol Cartwright For further information oblige drop by:
Best Generic medicines buy on AmPills.com penis enlargement
Yesterday I found interesting things about medicine alternative
0 comments:
Post a Comment